

Hui Feng

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11162360/publications.pdf>

Version: 2024-02-01

27
papers

2,977
citations

361413

20
h-index

526287

27
g-index

28
all docs

28
docs citations

28
times ranked

5300
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety, Efficacy, and Biomarker Analysis of Toripalimab in Patients with Previously Treated Advanced Urothelial Carcinoma: Results from a Multicenter Phase II Trial POLARIS-03. <i>Clinical Cancer Research</i> , 2022, 28, 489-497.	7.0	36
2	A non-ACE2-blocking neutralizing antibody against Omicron-included SARS-CoV-2 variants. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 23.	17.1	11
3	Etesevimab in combination with JS026 neutralizing SARS-CoV-2 and its variants. <i>Emerging Microbes and Infections</i> , 2022, 11, 548-551.	6.5	8
4	Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis. , 2022, 10, e004036.		24
5	Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial. <i>Cancer Cell</i> , 2022, 40, 277-288.e3.	16.8	177
6	Quality comparability assessment of a SARS-CoV-2-neutralizing antibody across transient, mini-pool-derived and single-clone CHO cells. <i>MAbs</i> , 2022, 14, 2005507.	5.2	8
7	Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02). <i>Journal of Clinical Oncology</i> , 2021, 39, 704-712.	1.6	156
8	Tolerability, Safety, Pharmacokinetics, and Immunogenicity of a Novel SARS-CoV-2 Neutralizing Antibody, Etesevimab, in Chinese Healthy Adults: a Randomized, Double-Blind, Placebo-Controlled, First-in-Human Phase I Study. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0035021.	3.2	18
9	A broadly neutralizing humanized ACE2-targeting antibody against SARS-CoV-2 variants. <i>Nature Communications</i> , 2021, 12, 5000.	12.8	37
10	Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial. <i>Nature Medicine</i> , 2021, 27, 1536-1543.	30.7	197
11	Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: a multicenter phase-II trial. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 355.	17.1	45
12	A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. <i>Nature</i> , 2020, 584, 120-124.	27.8	1,237
13	Safety and clinical efficacy of toripalimab, a PD-1 mAb, in patients with advanced or recurrent malignancies in a phase I study. <i>European Journal of Cancer</i> , 2020, 130, 182-192.	2.8	46
14	Safety, Efficacy, and Biomarker Analysis of Toripalimab in Previously Treated Advanced Melanoma: Results of the POLARIS-01 Multicenter Phase II Trial. <i>Clinical Cancer Research</i> , 2020, 26, 4250-4259.	7.0	104
15	Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G ₄ Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 2987-2999.	1.6	126
16	Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients. <i>Journal of Hematology and Oncology</i> , 2019, 12, 7.	17.0	113
17	Glycosylation-independent binding of monoclonal antibody toripalimab to FG loop of PD-1 for tumor immune checkpoint therapy. <i>MAbs</i> , 2019, 11, 681-690.	5.2	30
18	A novel bicistronic gene design couples stable cell line selection with a fucose switch in a designer CHO host to produce native and afucosylated glycoform antibodies. <i>MAbs</i> , 2018, 10, 416-430.	5.2	13

#	ARTICLE	IF	CITATIONS
19	Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1024-1038.	4.1	31
20	Preclinical evaluation of the efficacy, pharmacokinetics and immunogenicity of JS-001, a programmed cell death protein-1 (PD-1) monoclonal antibody. <i>Acta Pharmacologica Sinica</i> , 2017, 38, 710-718.	6.1	38
21	A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy. <i>Cancer Cell</i> , 2016, 29, 117-129.	16.8	281
22	Neuronal and Intestinal Protein Kinase D Isoforms Mediate Na ⁺ (Salt Taste)-Induced Learning. <i>Science Signaling</i> , 2009, 2, ra42.	3.6	19
23	Protein Kinase D Is an Essential Regulator of <i>C. elegans</i> Innate Immunity. <i>Immunity</i> , 2009, 30, 521-532.	14.3	75
24	Properties, Regulation, and in Vivo Functions of a Novel Protein Kinase D. <i>Journal of Biological Chemistry</i> , 2007, 282, 31273-31288.	3.4	37
25	Conserved Domains Subserve Novel Mechanisms and Functions in DKF-1, a <i>Caenorhabditis elegans</i> Protein Kinase D. <i>Journal of Biological Chemistry</i> , 2006, 281, 17815-17826.	3.4	14
26	Characterization of a Novel Protein Kinase D. <i>Journal of Biological Chemistry</i> , 2006, 281, 17801-17814.	3.4	21
27	Characterization of the Targeting, Binding, and Phosphorylation Site Domains of an A Kinase Anchor Protein and a Myristoylated Alanine-rich C Kinase Substrate-like Analog That Are Encoded by a Single Gene. <i>Journal of Biological Chemistry</i> , 1999, 274, 27201-27210.	3.4	38